Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the PVP protocol, combining Peptichemio, vincristine, and 6-methylprednisolone, resulted in remission for diffuse non-Hodgkin's lymphomas with moderate side effects.

This study found that taurine and apocynin together created a synergistic effect by significantly reducing burn area damage and enhancing tissue recovery in the burn zone of stasis in rats by day 21.

In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.

This study found that co-drugs synthesized from hydroquinone and tranexamic acid improved skin targeting and deposition, with reduced irritation and enhanced efficacy for treating hyperpigmentation.

This review discusses the potential of cold atmospheric plasma as a selective antitumor therapy for breast cancer but reports no clinical results, emphasizing its promise and the challenges to its use in precision oncology.

Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.

In this study, itraconazole was reported to effectively alleviate clinical symptoms in patients with recalcitrant Trichophyton rubrum infections, though toenail infections often recurred, indicating the need for further research on long-term efficacy and safety.

This study found that etoposide enhances the radiosensitivity of CT26 colorectal adenocarcinoma in BALB/c mice, significantly inhibiting tumor growth without significant toxicity.

This study found that using valproic acid during radiotherapy for glioma was associated with delayed hair loss and improved survival outcomes.

This study discusses a rare case of subacute cutaneous lupus erythematosus induced by nab-paclitaxel, a complication scarcely reported in existing literature related to paclitaxel use.

This article reviews the treatment options for tinea capitis, suggesting that itraconazole, terbinafine, and fluconazole are effective and safe alternatives to griseofulvin but reports no new clinical results.

In this ex vivo and mouse model study, Tofacitinib-loaded nanoparticles demonstrated enhanced delivery of the drug into hair follicles and reduced inflammatory effects compared to conventional forms, indicating potential for safer, topical use in treating alopecia areata.

This case report highlights the rare occurrence of life-threatening aplastic anemia in a 65-year-old woman treated with temozolomide for glioblastoma multiforme, emphasizing the need for more frequent blood monitoring to detect severe bone marrow suppression early.

This study found that first-line treatment with docetaxel and carboplatin was safe and effective for elderly patients with advanced non-selective non-small-cell lung cancer, showing an overall efficacy rate of 47.87%.

This article reviews skin toxicity classifications and management in patients undergoing molecularly targeted therapy, noting significant dermatotropic side effects associated with Epidermal Growth Factor Receptor Inhibitors.

This study at Gajra Raja Medical College found that topical methotrexate with tretinoin was more effective but not significantly better than betamethasone with tretinoin for treating alopecia areata over six months, with similar safety profiles between the treatments.

Low-intensity ultrasound may help protect hair follicles from chemotherapy-induced hair loss.

In this study, ritlecitinib was generally well tolerated in pediatric alopecia areata patients aged 6 to <12 years, with no severe or serious adverse events reported, and the drug's pharmacokinetic parameters were successfully characterized.

This report describes a case where a woman developed bronchiolitis obliterans organizing pneumonia and lupus potentially induced by carbamazepine, a reaction not previously documented.

This study found that a PEEP of 10 mbar for 2 hours did not adversely affect liver function or gastric mucosal perfusion in patients after cardiac surgery, as long as cardiac output was maintained.

This study observed that conjugates of the anticancer drug raltitrexed with dextran and albumin were more cytotoxic than the free drug at high concentrations, altering cell cycle effects.

This article reviews the characteristics and treatment options for various dermatophyte infections, highlighting that systemic treatment is essential for tinea capitis while topical treatments are generally effective for other types.

This study found that dabrafenib was well tolerated and led to durable responses in patients with BRAF-mutant differentiated thyroid carcinoma, with a median progression-free survival of 11.3 months.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

In this study, patients with resistant alopecia areata treated with 35% trichloroacetic acid showed significantly better outcomes compared to those receiving superficial cryotherapy, with TCA demonstrating "excellent" results in 37.5% of cases versus 6.25% for cryotherapy.

This article discusses recent advancements in treatments for psoriasis, including new drug approvals and innovative therapeutic approaches, but reports no new clinical results.

In this study, gelatin-coated transferosomes were developed to deliver tofacitinib specifically to hair follicles, resulting in 80% hair regrowth in alopecia areata patients with recalcitrant lesions after 12 weeks of treatment.

This review discusses the intracellular activity of β-thymosins and their role in modulating the actin cytoskeleton, but it reports no new experimental results.

This study reports that chemotherapy-induced hair loss affects up to 65% of patients, typically within 1 to 3 weeks of treatment, while scalp cooling may help prevent severe hair loss with taxane-based therapies.

This article describes cutaneous reactions including keratosis pilaris-like eruptions in a patient on nilotinib for chronic myelogenous leukemia, emphasizing the importance of accurately classifying such eruptions.